Ganciclovir

C. diff Risk

None

Oral Bioavailability

NA

Approximate Cost

$72.18

Dosing

5 mg/kg IV q24h
Prophylaxis/Maintenance Dose

5 mg/kg IV q12h
Treatment/Induction Dose

General Information

Common Usage

CMV infections

Drug Monitoring

CBC with differential twice weekly.

Serum creatinine once weekly.

Adverse Effects

May cause blood dyscrasias:

  • Granulocytopenia
  • Anemia
  • Thrombocytopenia.

Usually within first 1-2 weeks of treatment. Generally resolves within 3-7 days of discontinuation.

Tablet/Capsule Strengths

  • N/A
  • May be available through Ambulatory Treatment Center

Additional Information

Hazardous drug must be prepared by Pharmacy

Prepared in 100 mL NS. Infuse over 60 min

EH Prescribing Restrictions
None

Community IV Formulary (Metro Area)
NO

Pharmacology

Antimicrobial class: Antiviral, binds DNA polymerase to inhibit viral DNA synthesis.

Pregnancy category: C - animal studies have demonstrated carcinogenic and teratogenic effects.